Peptamen 1.3 PHGG
Dietary SupplementThe amount of tube feed will be assess by the health Care Professional.
NCT Number: NCT06102135
Enterally fed adults with documented evidence of gastrointestinal intolerance will be recruited. Participants will be deemed by the investigator as having a clinical indication for enteral feeding with a fibre containing peptide formula. Data from 15 participants are required in order to submit an application to the Advisory Committee on Borderline Substances (ACBS) for product registration.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Nutrition and Dietetics, Liverpool, United Kingdom
To evaluate the acceptability (including gastrointestinal tolerance and compliance) of an adult enteral peptide formula containing Partially Hydrolysed Guar Gum (PHGG) fibre in 15 patients. This is a single arm, prospective, multi-centre study to evaluate the gastrointestinal tolerance and compliance over a fourteen-day period. Data will be collected using patient diaries to asses changes in GI tolerance and tube feed intake.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The amount of tube feed will be assess by the health Care Professional.
Time frame: 14 days
Daily assessment of diarrhoea, constipation, reflux, vomiting, wind, bloating
Time frame: 14 days
mL
Société des Produits Nestlé (SPN)
Industry
To Evaluate the Acceptability (including Gastrointestinal Tolerance and Compliance) of an Adult Peptide 1.3 Kcal/ml Tube-feed Formula Containing Partially Hydrolysed Guar Gum (PHGG) Fibre.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05549622
Atrophy, Communicable Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT04247009
Arthritis, Arthritis, Rheumatoid
Gothenburg, Not in US/Canada, Sweden
View Trial DetailsNCT06173271
Atrophy, Behavior
Taichung, Baseline and Post Test of Intervention, Taiwan
View Trial DetailsNCT04518930
Appetitive Behavior, Behavior
Salt, Balqa Governorate, Jordan
View Trial Details